9 results on '"Andrews HN"'
Search Results
2. Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK).
- Author
-
Santos ND, Habibi G, Wang M, Law JH, Andrews HN, Wei D, Triche T, Dedhar S, and Dunn SE
- Abstract
Urokinase-type plasminogen activator (uPA) is associated with cancer recurrence where the most evidence comes from studies in breast cancer. According to the European Organization for Research and Treatment of Cancer, uPA is considered one of the most prominent biomarkers for cancer recurrence and therefore new agents are needed to inhibit it. Whether uPA is also expressed in pediatric cancers is yet unknown. If it is then uPA inhibitors might also help children with recurrent cancers. In this study, we addressed whether the integrin-linked kinase inhibitor (ILK), QLT0267, could suppress uPA. We previously showed that uPA expression is maximally inhibited when both the Akt and MAP kinase pathways were blocked which we anticipated can be achieved via QLT0267. In MDA-MB-231 breast cancer cells, QLT0267 blocked signaling through Akt and MAP kinase with a correlative decrease in uPA protein and mRNA, which corresponded to an inhibition of c-Jun phosphorylation. Consistent with these findings, cellular invasion was inhibited with either QLT0267 or with small interfering RNA against ILK. We then questioned whether uPA was commonly expressed in childhood sarcomas and if QLT0267 might be effective in this setting. We determined for the first time that uPA was highly expressed in rhabdomyosarcomas (RMS), but not Ewings sarcomas by screening cell lines (n = 31) and patient samples (n = 200) using Affymetrix microarrays. In alveolar RMS (ARMS) cell lines, QLT0267 blocked cell signaling, uPA production, invasion and ultimately survival. We concluded that QLT0267 blocks the production of uPA providing a new target for the management of recurrent cancers.
- Published
- 2007
3. Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
- Author
-
Andrews HN, Habibi G, Kucab JE, and Dunn SE
- Subjects
- Celecoxib, Cell Line, Tumor, Cell Proliferation drug effects, Dose-Response Relationship, Drug, Humans, Mitogen-Activated Protein Kinase 1 drug effects, Mitogen-Activated Protein Kinase 3 drug effects, Proto-Oncogene Proteins c-akt drug effects, RNA, Messenger drug effects, Signal Transduction drug effects, Urokinase-Type Plasminogen Activator genetics, Breast Neoplasms drug therapy, Cyclooxygenase Inhibitors pharmacology, Pyrazoles pharmacology, Sulfonamides pharmacology, Urokinase-Type Plasminogen Activator antagonists & inhibitors
- Abstract
Elevated urokinase-type plasminogen activator (uPA) expression in breast tumors predicts poor survival. We found celecoxib (25 microM) significantly reduced uPA protein and mRNA in MDA-MB-231 breast cancer cells following 72 h of treatment. Celecoxib also inhibited cell viability (12.5 and 25 microM) and induced G2M arrest (25 microM). Therefore, celecoxib therapy for uPA positive breast cancer should be explored.
- Published
- 2005
- Full Text
- View/download PDF
4. BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.
- Author
-
Gilmore PM, McCabe N, Quinn JE, Kennedy RD, Gorski JJ, Andrews HN, McWilliams S, Carty M, Mullan PB, Duprex WP, Liu ET, Johnston PG, and Harkin DP
- Subjects
- BRCA1 Protein biosynthesis, BRCA1 Protein genetics, Binding Sites, Breast Neoplasms drug therapy, Breast Neoplasms enzymology, Breast Neoplasms genetics, Cell Line, Tumor, Enzyme Activation drug effects, Humans, MAP Kinase Kinase Kinase 3, Plasmids genetics, Protein Structure, Tertiary, Antineoplastic Agents, Phytogenic pharmacology, BRCA1 Protein metabolism, MAP Kinase Kinase Kinases metabolism, Paclitaxel pharmacology
- Abstract
BRCA1 has been implicated in a number of cellular processes, including transcriptional regulation, DNA damage repair, cell cycle arrest, and apoptosis. We identified mitogen-activated protein kinase (MAPK) kinase kinase 3 (MEKK3), an upstream regulator of the c-Jun NH(2)-terminal kinase/stress-activated protein kinase and p38/MAPK pathways, as a novel BRCA1-interacting protein in a yeast two-hybrid screen and confirmed the interaction by coimmunoprecipitation in mammalian cells. Deletion mapping demonstrated that amino acids 1611-1863 are required to mediate the interaction with MEKK3 in yeast. BRCA1 disease-associated mutations abrogated the interaction in yeast, and BRCA1 failed to interact with MEKK3 in BRCA1 mutant HCC1937 breast cancer cells. We demonstrate that small interfering RNA-based inhibition of endogenous BRCA1 reduces MEKK3 kinase activity and conversely that inducible expression of BRCA1 activates MEKK3 and p38/MAPK. Finally, we demonstrate using complementary approaches that BRCA1 is required for paclitaxel-induced activation of MEKK3. These data indicate that BRCA1 is a key regulator of the paclitaxel-induced stress response pathway and suggest that the ability of BRCA1 to associate with, and mediate the activation of, MEKK3 represents a potential mechanism through which this pathway is regulated.
- Published
- 2004
- Full Text
- View/download PDF
5. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin.
- Author
-
Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik CD, Brookes C, Neckers LM, Evdokimova V, Huntsman DG, and Dunn SE
- Subjects
- Antineoplastic Agents therapeutic use, Base Sequence, Benzoquinones, Breast Neoplasms mortality, Breast Neoplasms pathology, DNA Primers, Female, Follow-Up Studies, Humans, Lactams, Macrocyclic, Neoplasm Staging, Predictive Value of Tests, Prognosis, Protein Serine-Threonine Kinases antagonists & inhibitors, RNA, Messenger genetics, Survival Analysis, Time Factors, Tumor Cells, Cultured, Breast Neoplasms genetics, Gene Expression Regulation, Neoplastic genetics, Receptor, IGF Type 1 genetics, Rifabutin analogs & derivatives, Rifabutin therapeutic use, Urokinase-Type Plasminogen Activator genetics
- Abstract
Urokinase plasminogen activator (uPA) expression in breast cancer is associated with relapse and a reduction in disease-specific survival. Thus, efforts are under way to identify uPA inhibitors. By screening a chemical library of >1000 compounds, 17-allyaminogeldanamycin (17AAG) was identified as a potent inhibitor of uPA by the National Cancer Institute and is now in Phase I clinical trials. At this time, it remains unclear how 17AAG blocks uPA; one possibility is through disruption of the insulin-like growth factor I receptor (IGF-IR) pathway. This would be consistent with studies from our laboratory showing that activation of IGF-IR results in the induction of uPA protein. In the study described herein, we observed that IGF-IR and uPA were highly expressed in 87 and 55% of breast cancer by screening tumor tissue microarrays representing 930 cases. A significant proportion (52.1% = 354 of 680 cases, P < 0.0001) of the patients had tumors expressing both proteins. uPA alone (P = 0.033) or in combination with IGF-IR (P = 0.0104) was indicative of decreased disease-specific survival. Next, we demonstrated that treating MDA-MB-231 cells with increasing concentrations of 17AAG resulted in IGF-IR degradation (IC(50) = 1.0 micro M) and blocked signal transduction through the Akt and mitogen-activated protein kinase pathways. Finally, we found that 17AAG had a robust inhibitory effect on the production of uPA mRNAand protein in the presence of IGF-I. Thus, our study raises the possibility that 17AAG could prove to be an effective therapeutic agent for a large number of breast cancer patients by inhibiting the IGF-IR and ultimately uPA.
- Published
- 2004
- Full Text
- View/download PDF
6. Role played by BRCA1 in regulating the cellular response to stress.
- Author
-
Gilmore PM, Quinn JE, Mullan PB, Andrews HN, McCabe N, Carty M, Kennedy RD, and Harkin DP
- Subjects
- Animals, Apoptosis, Blotting, Northern, Cell Cycle, G2 Phase, Humans, Interferon-gamma metabolism, JNK Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinases metabolism, Mitosis, Paclitaxel pharmacology, Stress, Physiological, Time Factors, Tumor Cells, Cultured, Tumor Suppressor Protein p53 metabolism, Ultraviolet Rays, BRCA1 Protein physiology, DNA Damage, DNA Repair, Genes, BRCA1, Transcription, Genetic
- Abstract
BRCA1 (breast-cancer susceptibility gene 1) is a tumour suppressor gene that is mutated in the germline of women with a genetic predisposition to breast and ovarian cancer. In this review, we examine the role played by BRCA1 in mediating the cellular response to stress. We review the role played by BRCA1 in detecting and signalling the presence of DNA damage, particularly double-strand DNA breaks, and look at the evidence to support a role for BRCA1 in regulating stress response pathways such as the c-Jun N-terminal kinase/stress-activated protein kinase pathway. In addition, we examine the role played by BRCA1 in mediating both cell-cycle arrest and apoptosis following different types of cellular insult, and how this may be modulated by the presence or absence of associated proteins such as p53. Finally, we explore the possibility that many of the functions associated with BRCA1 may be based on transcriptional regulation of key downstream genes that have been implicated in the regulation of these specific cellular pathways.
- Published
- 2003
- Full Text
- View/download PDF
7. BRCA1 regulates the interferon gamma-mediated apoptotic response.
- Author
-
Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, Haber DA, and Harkin DP
- Subjects
- BRCA1 Protein genetics, Blotting, Western, Cell Line, DNA-Binding Proteins biosynthesis, Gene Expression Regulation, Humans, Interferon Regulatory Factor-7, Myxovirus Resistance Proteins, Oligonucleotide Array Sequence Analysis, Protein Biosynthesis, Up-Regulation, Apoptosis, GTP-Binding Proteins, Genes, BRCA1 physiology, Interferon-gamma physiology
- Abstract
BRCA1 is a tumor suppressor gene implicated in transcriptional regulation. We have generated cell lines with inducible expression of BRCA1 as a tool to identify downstream targets that may be important mediators of BRCA1 function. Oligonucleotide array-based expression profiling identified 11 previously described interferon regulated genes that were up-regulated following inducible expression of BRCA1. Northern blot analysis revealed that a subset of the identified targets including IRF-7, MxA, and ISG-54 were synergistically up-regulated by BRCA1 in the presence of interferon gamma (IFN-gamma) but not interferons alpha or beta. Importantly, IFN-gamma-mediated induction of IRF-7 and MxA was attenuated in the BRCA1 mutant cell line HCC1937, an effect that was rescued following reconstitution of exogenous wild type BRCA1 in these cells. Furthermore, reconstituted BRCA1 sensitized HCC1937 cells to IFN-gamma-induced apoptotic cell death. This study identifies BRCA1 as a component of the IFN-gamma-regulated signaling pathway and suggests that BRCA1 may play a role in the regulation of IFN-gamma-mediated apoptosis.
- Published
- 2002
- Full Text
- View/download PDF
8. Effect of social housing condition on heat shock protein (HSP) expression in the Shionogi mouse mammary carcinoma (SC115).
- Author
-
Andrews HN, Kerr LR, Strange KS, Emerman JT, and Weinberg J
- Subjects
- Animals, Blotting, Western, Cell Division, Disease Models, Animal, Male, Mammary Neoplasms, Experimental complications, Mammary Neoplasms, Experimental pathology, Mice, Mice, Inbred Strains, Stress, Physiological complications, Tumor Cells, Cultured, Heat-Shock Proteins metabolism, Housing, Animal, Mammary Neoplasms, Experimental metabolism, Stress, Physiological metabolism
- Abstract
Our previous studies have shown that social housing conditions can significantly alter the growth rate of the Shionogi mouse mammary carcinoma (SC115). The present study extended our investigations to the molecular level by examining stressor effects on the expression of a group of stress-responsive proteins, the heat shock proteins (HSPs). We hypothesized that HSP expression in SC115 cells may be altered by (a) different social housing conditions in vivo and (b) steroid hormone and growth factor exposure in vitro. Mice were reared in groups (G) or as individuals (I). Immediately following tumor cell injection, mice were rehoused from group to individual (GI), from individual to group (IG), or they remained in groups (GG). Tumor tissue was resected at 0.8 g or 3.0 g, as evidence suggests that tumor size affects HSP expression, which in turn affects proliferation. The data demonstrate that expression of HSP25, 70, and 90 was increased in tumors from mice in the IG compared to GG and GI mice, at both tumor weights examined. In addition, in IG mice, HSP90 expression was greater in 0.8 g compared to 3.0 g tumors. Under controlled culture conditions, hormones known to stimulate SC115 growth both in vivo and in vitro altered HSP expression. Physiological levels of dihydrotestosterone (DHT) and pharmacological levels of hydrocortisone (HC) upregulated expression of HSP25, whereas physiological levels of beta-estradiol (E2) upregulated expression of HSP90. These data are the first to demonstrate that a psychosocial stressor, a change in social housing condition, can induce differential HSP expression. Further, these data show that hormones that regulate SC115 tumor growth, also alter HSP expression.
- Published
- 2000
- Full Text
- View/download PDF
9. Psychosocial stressors and mammary tumor growth: an animal model.
- Author
-
Strange KS, Kerr LR, Andrews HN, Emerman JT, and Weinberg J
- Subjects
- Animals, Antineoplastic Agents therapeutic use, Disease Models, Animal, Endocrine Glands physiopathology, Female, Heat-Shock Proteins physiology, Humans, Immune System physiopathology, Killer Cells, Natural immunology, Male, Mammary Neoplasms, Experimental drug therapy, Mice, Social Behavior, Social Conditions, Stress, Psychological, Mammary Neoplasms, Experimental pathology, Mammary Neoplasms, Experimental psychology
- Abstract
Stressful life events and the ability to cope with stress may play a role in the progression of breast cancer; however, the complex relationship between stressors and tumor growth is difficult to investigate in humans. Our studies have utilized the androgen-responsive Shionogi mouse mammary carcinoma (AR SC115) in male mice to investigate the effects of social housing condition on tumor growth rates and responses to chemotherapy. We demonstrate that, depending on social housing condition, mammary tumor growth and response to chemotherapy can both increase and decrease. We have examined the possible role(s) of 1) psychosocial variables, 2) testosterone and corticosterone, hormones altered by stress and known to stimulate SC115 cells in vivo and in vitro, 3) NK cells, one of the body's first lines of defense against tumor cells, 4) stress proteins, in mediating the differential tumor growth rates observed in our model. This review discusses the investigations we have undertaken to elucidate the mechanisms through which a psychosocial stressor, social housing condition, can alter tumor growth rate.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.